€42.20
0.00%
Xetra, Tue, Jun 10 2025
ISIN
DE0005227201
Symbol
BIO
Index
Sector

Key metrics

Basic
Market capitalization
€1.4b
Enterprise Value
€2.0b
Net debt
€608.9m
Cash
€59.8m
Shares outstanding
39.6m
Valuation (TTM | estimate)
P/E
- | -
P/S
2.2 | 1.9
EV/Sales
3.2 | 2.8
EV/FCF
139.6
P/B
2.8
Dividends
DPS
€0.00
Yield 1Y | 5Y
0.0% | 0.0%
Growth 1Y | 5Y
- | -
Payout 1Y | 3Y
0.0% | 0.0%
Increased
0 Years
Financials (TTM | estimate)
Revenue
€635.2m | €719.1m
EBITDA
- | €149.5m
EBIT
€11.9m | €108.1m
Net Income
€-24.5m | €60.0m
Free Cash Flow
€14.4m
Growth (TTM | estimate)
Revenue
-15.9% | -1.0%
EBITDA
- | 55.7%
EBIT
-93.3% | 24.8%
Net Income
-116.4% | 127.1%
Free Cash Flow
-37.4%
Margin (TTM | estimate)
Gross
23.2%
EBITDA
- | 20.8%
EBIT
1.9%
Net
-3.9% | 8.3%
Free Cash Flow
2.3%
Financial Health
Equity Ratio
37.0%
Return on Equity
5.0%
ROCE
1.0%
ROIC
0.9%
Debt/Equity
1.3
More
EPS
€-0.6
FCF per Share
€0.4
Short interest
-
Employees
2k
Rev per Employee
€290.0k
Show more

Is Biotest a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Biotest Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Biotest forecast:

3x Hold
43%
4x Sell
57%

Analyst Opinions

7 Analysts have issued a Biotest forecast:

Hold
43%
Sell
57%

Financial data from Biotest

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
635 635
16% 16%
100%
- Direct Costs 488 488
12% 12%
77%
147 147
54% 54%
23%
- Selling and Administrative Expenses 86 86
4% 4%
13%
- Research and Development Expense 57 57
20% 20%
9%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 12 12
93% 93%
2%
Net Profit -25 -25
116% 116%
-4%

In millions EUR.

Don't miss a Thing! We will send you all news about Biotest directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biotest Stock News

AD HOC NEWS
3 months ago
Grifols Biotest Holdings GmbH / DE0005227201, DE000522723
AD HOC NEWS
3 months ago
Grifols Biotest Holdings GmbH / DE0005227201, DE000522723

Company Profile

Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.

Head office Germany
CEO Peter Janssen
Employees 2,495
Founded 1946
Website www.biotest.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today